Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.76 USD | -7.88% | -6.20% | +33.33% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 29.85M |
---|---|---|---|---|---|
Net income 2024 * | -62M | Net income 2025 * | -83M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.66
x | P/E ratio 2025 * |
-0.7
x | Employees | 40 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.2% |
Latest transcript on Viracta Therapeutics, Inc.
1 day | -7.88% | ||
1 week | -6.20% | ||
Current month | -7.27% | ||
1 month | -33.91% | ||
3 months | +17.65% | ||
6 months | +31.03% | ||
Current year | +33.33% |
Managers | Title | Age | Since |
---|---|---|---|
Mark Rothera
CEO | Chief Executive Officer | 62 | 22-09-18 |
Melody Burcar
DFI | Director of Finance/CFO | 41 | 22-08-31 |
Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Ivor Royston
BRD | Director/Board Member | 79 | 07-09-30 |
Thomas Darcy
BRD | Director/Board Member | 74 | 21-01-31 |
Barry Simon
BRD | Director/Board Member | 69 | 21-03-02 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 0.76 | -7.88% | 89,167 |
24-05-09 | 0.825 | +0.49% | 56,573 |
24-05-08 | 0.821 | +0.12% | 26,829 |
24-05-07 | 0.82 | +2.49% | 22,920 |
24-05-06 | 0.8001 | -1.25% | 38,197 |
Delayed Quote Nasdaq, May 10, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+33.33% | 29.85M | |
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+46.73% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- VIRX Stock